BERLIN — In June, Amgen reported that an experimental drug had hit the main goal of a gastric cancer study, improving overall survival in “a statistically significant and clinically meaningful” way. It said it would provide more detailed results from the interim analysis later on.
Then the situation took an unusual turn.
Last month, the company disclosed that a follow-up analysis showed that the survival benefit of the drug, called bemarituzumab, had shrunk, leading to questions about why. There were also concerns about possible safety issues, including known eye-related side effects.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply